BioMarin Pharma (BMRN) Misses Q4 EPS Views
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $58.38 -1.39%
EPS Growth %: -34.0%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
CCEL, FNGR, FAST, More
EPS Growth %: -34.0%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.39, $0.60 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $227.9 million versus the consensus estimate of $224.38 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.05-1.10 billion, versus the consensus of $1.15 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup (C) Tops Q2 EPS by 42c
- Tractor Supply Company (TSCO) PT Lowered to $33 at UBS
- U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
